Biogen Idec Inc (BIIB) 320.60 $BIIB
Biogen Idec Set to Possibly Rebound After Yesterday's Selloff of 1.41%
Comtex SmarTrend(R) - Thu Aug 07, 3:51PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $319.80 to a high of $327.36. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $322.00 on volume of 864,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
The Launch of Five Immunomodulatory Therapies for Relapsing Forms of Multiple Sclerosis Will Contribute to 4 Percent Annual Growth of the Total Market from 2013 to 2023
PR Newswire - Thu Aug 07, 12:00PM CDT
Decision Resources Group finds that the forecast launch of Biogen Idec's Plegridy, Roche/Genentech's ocrelizumab, Biogen Idec/AbbVie's daclizumab, Teva/Active Biotech's Nerventra and Receptos' RPC-1063, coupled with the expected U.S. approval of Genzyme/Sanofi/Bayer HealthCare's Lemtrada, will help drive total sales across the multiple sclerosis (MS) market in the United States, France, Germany, Italy, Spain, United Kingdom and Japan to over $20 billion in 2023, reflecting 4 percent annual growth from 2013. Of note, future generics and projected biosimilar competition will cause major-market sales to contract in the latter part of our study period from a 2018 peak of over $22 billion.
TECFIDERA(TM), a First-Line Oral Treatment for Multiple Sclerosis, Reimbursed in Alberta
CNW Group - Thu Aug 07, 9:00AM CDT
Biogen Idec Canada announces today that Alberta Health will now reimburse TECFIDERATM (dimethyl fumarate) through the Alberta Drug Benefit List (DBL). TECFIDERATM is a first-line oral treatment for adults with relapsing-remitting multiple sclerosis (RRMS). TECFIDERATM is indicated as monotherapy for the treatment of RRMS to reduce the frequency of clinical exacerbations and to delay the progression of disability.(1)
Isis Pharmaceuticals Posts Narrower-Than-Expected Q2 Loss - Analyst Blog
Arpita Dutt - Zacks Investment Research - Thu Aug 07, 8:10AM CDT
Isis Pharmaceuticals (ISIS) remains on track to deliver revenues of more than $160 million this year.
Regulus Reports Second Quarter 2014 Financial Results and Recent Highlights
PR Newswire - Wed Aug 06, 3:05PM CDT
Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today reported financial results and highlights for the quarter ended June 30, 2014 and provided a summary of recent corporate highlights.
Five Large Caps With Earnings Growth Of 25% Or More
at The Street - Tue Aug 05, 10:46AM CDT
By James Dennin for Kapitall. A survey of the Fortune 500 by the Wall Street Journal says that United States companies [...]
Regulus Enters Into New Collaboration Agreement with Biogen Idec to Identify microRNA Biomarkers in Multiple Sclerosis
PR Newswire - Tue Aug 05, 7:00AM CDT
Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that it has entered into a new collaboration agreement with Biogen Idec (NASDAQ: BIIB) to expand its research focused on identifying microRNAs as biomarkers for multiple sclerosis (MS) under its Regulus microMarkers(TM) division. The new research will focus on profiling a large number of whole blood samples from a cohort of MS patients who have been treated with a Biogen Idec MS therapy to identify potential microRNA signatures. Regulus will receive $2M upfront and is eligible for future payments upon achievement of certain milestones related to the identification of potential microRNA signatures.
Acorda Beats on Q2 Earnings & Revenues, Maintains View - Analyst Blog
Arpita Dutt - Zacks Investment Research - Mon Aug 04, 8:20AM CDT
Acorda (ACOR) recorded an improvement in Ampyra revenues and continues to expect Ampyra sales in the range of $328 million - $335 million.
BioMed Realty Trust To Webcast Investor Day 2014
PR Newswire - Mon Aug 04, 7:00AM CDT
BioMed Realty Trust, Inc. (NYSE: BMR) will webcast its Investor Day 2014 program to be held on Wednesday, August 6, 2014 at the New York Stock Exchange.
Biotech Gets A Lift On Popular Drug, Strong Pipeline
at Investor's Business Daily - Fri Aug 01, 6:13PM CDT
The success of Biogen Idec's (BIIB) oral multiple sclerosis (MS) treatment Tecfidera has been well documented in recent quarters, but the company is far from a one-hit wonder. Its biggest seller is Avonex, an injectable MS treatment. Other Biogen...
Stock Market News for August 01, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Fri Aug 01, 9:10AM CDT
Benchmarks suffered their biggest losses in months on Thursday, following a default by Argentina, and a spike in US labor costs
Favorable Court Ruling, Quarterly Performance Reviews, Acquisition Completion, and Contract Renewals - Research Reports on Mylan, Biogen, Medtronic, UnitedHealth and Covidien
PR Newswire - Fri Aug 01, 8:20AM CDT
Today, Analysts Review released its research reports regarding Mylan, Inc. (NASDAQ: MYL), Biogen Idec Inc. (NASDAQ: BIIB), Medtronic, Inc. (NYSE: MDT), UnitedHealth Group Inc. (NYSE: UNH) and Covidien plc (NYSE: COV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5370-100free.
Stock Market News for July 31, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 9:10AM CDT
Benchmarks ended Wednesday’s choppy trading session little changed after the Federal Reserve offered a mixed view on the economy
Increased Earnings Estimates Seen for Biogen Idec (BIIB): Can It Move Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 7:57AM CDT
Biogen Idec could be an interesting play for investors because of its positive short-term momentum and solid earnings estimate revisions
Biotech Valuations Are Low Not Stretched. Here's Why.
at The Street - Thu Jul 31, 7:35AM CDT
If biotech companies can assuage concerns about long-term growth, multiples might expand.
Biotech Stock Roundup: Gilead's Sovaldi & Biogen's Tecfidera Impressive Run Continues - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jul 30, 11:04AM CDT
Companies like Gilead and Biogen came out with impressive numbers thanks to the continued strong performance of new products.
Biogen Idec (BIIB) Highlighted As Momo Momentum Stock
at The Street - Wed Jul 30, 9:00AM CDT
Trade-Ideas LLC identified Biogen Idec (BIIB) as a momo momentum candidate
Proteostasis Therapeutics Announces Achievement of Preclinical Milestone in Neurodegenerative Diseases Collaboration With Biogen Idec
Marketwire - Wed Jul 30, 4:30AM CDT
Proteostasis Therapeutics, Inc., a company developing novel therapeutics that regulate protein homeostasis to improve outcomes for patients with orphan and neurodegenerative diseases, today announced that it has successfully completed a key preclinical milestone in the collaboration with Biogen Idec. Proteostasis has received a multimillion dollar milestone payment as a result of this achievement.
Biogen Idec Set to Possibly Rebound After Yesterday's Selloff of 1.41%
Comtex SmarTrend(R) - Thu Aug 07, 3:51PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $319.80 to a high of $327.36. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $322.00 on volume of 864,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
The Launch of Five Immunomodulatory Therapies for Relapsing Forms of Multiple Sclerosis Will Contribute to 4 Percent Annual Growth of the Total Market from 2013 to 2023
PR Newswire - Thu Aug 07, 12:00PM CDT
Decision Resources Group finds that the forecast launch of Biogen Idec's Plegridy, Roche/Genentech's ocrelizumab, Biogen Idec/AbbVie's daclizumab, Teva/Active Biotech's Nerventra and Receptos' RPC-1063, coupled with the expected U.S. approval of Genzyme/Sanofi/Bayer HealthCare's Lemtrada, will help drive total sales across the multiple sclerosis (MS) market in the United States, France, Germany, Italy, Spain, United Kingdom and Japan to over $20 billion in 2023, reflecting 4 percent annual growth from 2013. Of note, future generics and projected biosimilar competition will cause major-market sales to contract in the latter part of our study period from a 2018 peak of over $22 billion.
TECFIDERA(TM), a First-Line Oral Treatment for Multiple Sclerosis, Reimbursed in Alberta
CNW Group - Thu Aug 07, 9:00AM CDT
Biogen Idec Canada announces today that Alberta Health will now reimburse TECFIDERATM (dimethyl fumarate) through the Alberta Drug Benefit List (DBL). TECFIDERATM is a first-line oral treatment for adults with relapsing-remitting multiple sclerosis (RRMS). TECFIDERATM is indicated as monotherapy for the treatment of RRMS to reduce the frequency of clinical exacerbations and to delay the progression of disability.(1)
Isis Pharmaceuticals Posts Narrower-Than-Expected Q2 Loss - Analyst Blog
Arpita Dutt - Zacks Investment Research - Thu Aug 07, 8:10AM CDT
Isis Pharmaceuticals (ISIS) remains on track to deliver revenues of more than $160 million this year.
Regulus Reports Second Quarter 2014 Financial Results and Recent Highlights
PR Newswire - Wed Aug 06, 3:05PM CDT
Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today reported financial results and highlights for the quarter ended June 30, 2014 and provided a summary of recent corporate highlights.
Five Large Caps With Earnings Growth Of 25% Or More
at The Street - Tue Aug 05, 10:46AM CDT
By James Dennin for Kapitall. A survey of the Fortune 500 by the Wall Street Journal says that United States companies [...]
Regulus Enters Into New Collaboration Agreement with Biogen Idec to Identify microRNA Biomarkers in Multiple Sclerosis
PR Newswire - Tue Aug 05, 7:00AM CDT
Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that it has entered into a new collaboration agreement with Biogen Idec (NASDAQ: BIIB) to expand its research focused on identifying microRNAs as biomarkers for multiple sclerosis (MS) under its Regulus microMarkers(TM) division. The new research will focus on profiling a large number of whole blood samples from a cohort of MS patients who have been treated with a Biogen Idec MS therapy to identify potential microRNA signatures. Regulus will receive $2M upfront and is eligible for future payments upon achievement of certain milestones related to the identification of potential microRNA signatures.
Acorda Beats on Q2 Earnings & Revenues, Maintains View - Analyst Blog
Arpita Dutt - Zacks Investment Research - Mon Aug 04, 8:20AM CDT
Acorda (ACOR) recorded an improvement in Ampyra revenues and continues to expect Ampyra sales in the range of $328 million - $335 million.
BioMed Realty Trust To Webcast Investor Day 2014
PR Newswire - Mon Aug 04, 7:00AM CDT
BioMed Realty Trust, Inc. (NYSE: BMR) will webcast its Investor Day 2014 program to be held on Wednesday, August 6, 2014 at the New York Stock Exchange.
Biotech Gets A Lift On Popular Drug, Strong Pipeline
at Investor's Business Daily - Fri Aug 01, 6:13PM CDT
The success of Biogen Idec's (BIIB) oral multiple sclerosis (MS) treatment Tecfidera has been well documented in recent quarters, but the company is far from a one-hit wonder. Its biggest seller is Avonex, an injectable MS treatment. Other Biogen...
Stock Market News for August 01, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Fri Aug 01, 9:10AM CDT
Benchmarks suffered their biggest losses in months on Thursday, following a default by Argentina, and a spike in US labor costs
Favorable Court Ruling, Quarterly Performance Reviews, Acquisition Completion, and Contract Renewals - Research Reports on Mylan, Biogen, Medtronic, UnitedHealth and Covidien
PR Newswire - Fri Aug 01, 8:20AM CDT
Today, Analysts Review released its research reports regarding Mylan, Inc. (NASDAQ: MYL), Biogen Idec Inc. (NASDAQ: BIIB), Medtronic, Inc. (NYSE: MDT), UnitedHealth Group Inc. (NYSE: UNH) and Covidien plc (NYSE: COV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5370-100free.
Stock Market News for July 31, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 9:10AM CDT
Benchmarks ended Wednesday’s choppy trading session little changed after the Federal Reserve offered a mixed view on the economy
Increased Earnings Estimates Seen for Biogen Idec (BIIB): Can It Move Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 7:57AM CDT
Biogen Idec could be an interesting play for investors because of its positive short-term momentum and solid earnings estimate revisions
Biotech Valuations Are Low Not Stretched. Here's Why.
at The Street - Thu Jul 31, 7:35AM CDT
If biotech companies can assuage concerns about long-term growth, multiples might expand.
Biotech Stock Roundup: Gilead's Sovaldi & Biogen's Tecfidera Impressive Run Continues - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jul 30, 11:04AM CDT
Companies like Gilead and Biogen came out with impressive numbers thanks to the continued strong performance of new products.
Biogen Idec (BIIB) Highlighted As Momo Momentum Stock
at The Street - Wed Jul 30, 9:00AM CDT
Trade-Ideas LLC identified Biogen Idec (BIIB) as a momo momentum candidate
Proteostasis Therapeutics Announces Achievement of Preclinical Milestone in Neurodegenerative Diseases Collaboration With Biogen Idec
Marketwire - Wed Jul 30, 4:30AM CDT
Proteostasis Therapeutics, Inc., a company developing novel therapeutics that regulate protein homeostasis to improve outcomes for patients with orphan and neurodegenerative diseases, today announced that it has successfully completed a key preclinical milestone in the collaboration with Biogen Idec. Proteostasis has received a multimillion dollar milestone payment as a result of this achievement.
